Facebook
Twitter
LinkedIn
Forward- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.
Moderated by: Chris Ward
Inherited Platelet Disorders – Marco Cattaneo
Inherited Platelet Disorders (IPD) include Inherited Thrombocytopenias (IT) and Inherited Platelet Function Disorders (IPFD). IT are more common than generally believed and should not be confused with acquired thrombocytopenias, in order to avoid futile and potentially dangerous treatments. The bleeding manifestations of IT are very rarely severe. Some IT are associated with inherited defects in other organs or systems (syndromic IT). Inherited Platelet Function Disorders (IPFD) are also more common than generally believed. They may be associated with normal or decreased platelet cont. While clinicians should be aware of the main characteristics of IPD in order to raise the diagnostic suspicion, the definite diagnosis should be demanded to specialized laboratories, implementing complex diagnostic workups. The presentation will include a practical approach to the differential diagnosis of IT with acquired thrombocytopenias, the diagnostic workup management of IPFD. The target audience includes clinicians and laboratory personnel interested in the diagnosis and management of patients with bleeding diatheses. The participants will be more aware of the existence of IPD and will acquired some information on their diagnostic workups and clinical management.
Genetic basis of congenital macrothrombocytopenia – Shinji Kunishima
Recent progress in the elucidation of underlying defects and the developments of diagnostic tests has renewed our understanding of congenital macrothrombocytopenia. The condition is not rare as previously thought. This presentation will address the genetic and molecular basis of congenital macrothrombocytopenia. The presentation includes a practical approach to the differential diagnosis and description of recently identified forms. The participants will better understand the knowledge and diagnosis process of congenital macrothrombocytopenia.
- Basic scientists and clinicians interested in platelet function testing and genetics of platelet disorders
- Laboratory technicians involved in the diagnosis of hemorrhagic disorders
- Clinicians interested in platelet function disorders and genetics of platelet function disorders
At the conclusion of this activity, I will be able to:
- Discuss and describe the range of platelet function tests that can be utilized for the study of platelet function in the clinic
- Explain the advantages and limitations of available platelet function tests
- Distinguish the clinical conditions in which platelet function testing can be of help
- Use the rational laboratory diagnostic flow chart for the diagnosis of inherited platelet function disorders
Marco Cattaneo, MD, is Director of the Unit of Internal Medicine, Ospedale San Paolo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Italy.He graduated at the Medical School of Università degli Studi di Milano in 1975 and spoecialized in Hematology at Università di Pavia, Italy, in 1978. He was Post-Doctoral Fellow (1979-1981) and Visting Scientist (1983) at McMaster University, Hamilton (ONT), and Visiting Scientist at The Scripps Research Institute , La Jolla (CA) in 2000-2001. His reasearch is mostly focused on the pathophysiology of platelet fucntion and on the pjharmacology of antiplatelet agents.
Shinji Kunishima, PhD, is a chief of Laboratory of Molecular Diagnosis, Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.He graduated from Nagoya University College of Medical Technology in 1983. He received his PhD degree in Medicine at the first Department of Internal Medicine, Nagoya University, in 2001. He joined the staff of Clinical Research Center of Nagoya Medical Center in 2002. His research is focused on the genetic basis and differential diagnosis of congenital macrothrombocytopenias.Shinji Kunishima
Moderator Chris Ward Professor Chris Ward is a Clinical Haematologist and Head, Department of Haematology and Transfusion Medicine, Royal North Shore Hospital with research interests in coagulation and vascular biology. Prof. Ward is the Director of the Northern Blood Research Centre, supervising research in platelet function, hypercoagulability in cancer and other disease states, and global tests of coagulation. Prof Ward is the lead investigator for clinical trials of new anticoagulants and thrombopoietin agonists at RNS and contributes to pharmaceutical and public health advisory boards in this area. He represented the Royal Australasian College of Physicians on a national advisory panel, developing the 2009 NHMRC Clinical Practice Guideline on venous thrombosis prevention in Australian hospitals. He was President of the Australasian Society for Thrombosis and Haemostasis between 2007-9, and President of the 7th Congress of the Asia-Pacific Society on Thrombosis and Hemostasis in Melbourne, 2012.Chris Ward
Name | Company | Role |
Chris Ward, MD | Bayer | Advisory Board, Speaker |
Pfizer-BMS | Advisory Board, Speaker | |
Boehringer-Ingelheim | Advisory Board, Speaker | |
Alexion | Advisory Board | |
Medimark | Steering Committee Member, Speaker | |
Marco Cattaneo, MD | Astra Zeneca | Advisory Board, Speaker |
Eli Lilly | Advisory Board, Speaker | |
Daiichi Sankyo | Advisory Board, Speaker | |
Geoff Barnes | BMS, Pfizer, Blue Cross Blue Shield of Michigan | Primary Investigator & Co-Investigator |
Yukio Ozaki | Sysmex | Advisory Board |
|
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved